ClinicalTrials.gg
CompletedNCT05405582Updated Jul 6, 2026

Thetha Nami Ngithethe Nawe ("Let's Talk"): Step Wedge cRCT of Peer Led Community PrEP and SRH for Youth in South Africa

An interventional study of Community-based differentiated HIV prevention incl.PrEP with SRH and Primary Health Clinic based HIV prevention and care in HIV-1-infection and Sexually Transmitted Diseases, sponsored by Africa Health Research Institute. Completed at 1 site in South Africa. Open to participants aged 15 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Africa Health Research Institute · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8,716
Allocation
Randomized
Ages
15 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Sexually Transmitted Diseases with a site in South Africa — 2 open to participants now, 3 under way, 1 of them phase 3. Sexually Transmitted Diseases · South Africa.

Enrollment
Largest of 27
8,716 · median 564
Started
2022
with 1 other
No phase
15 of 30
2 open now
Registered
21st of 30
by date
Lead sponsor
2 of 30
Africa Health Research Institute

Among the 30 studies in Sexually Transmitted Diseases with a site in South Africa, this one has the largest enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2022, is one of 15 with no phase, and was the 21st registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

2 of the 30 studies in Sexually Transmitted Diseases with a site in South Africa are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: 15 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Sexually Transmitted Diseases with a site in South Africa, or all of them as a file.
02

Study summary

Study Hypothesis: Social mobilisation will attract and engage young people into decentralised sexual reproductive health (SRH) services where HIV prevention is tailored to need. Decentralised risk informed (differentiated) biosocial HIV prevention will reduce the overall prevalence of sexually transmissible HIV amongst young people aged 15-30.

Study aims:

  1. Measure the impact of social mobilisation into decentralised SRH services that provide tailored HIV prevention on the prevalence of transmissible HIV.
  2. Evaluate the acceptability, practicability, and reach of social mobilisation and decentralised SRH with tailored HIV prevention to deliver differentiated biosocial HIV prevention.

Study design: A step-wedge cluster randomised control trial comparing the effect of the Intervention (social mobilisation by peer navigators into mobile nurse-led SRH clinics) with Standard of Care (SoC) at Primary Health Care clinics, in reducing the proportion of 15-30 year olds with sexually transmissible HIV and increased uptake of risk-informed (differentiated) HIV prevention Intervention: Peer navigator social mobilisation intervention includes safe spaces, structured psychosocial and health needs assessment; Peer-mentorship with tailored health promotion, psychosocial support and lay-counselling; provision of condoms, HIV self-tests and pregnancy tests. The mobile SRH clinics provide sexually transmitted infection (STI) care, contraception, HIV testing and antiretroviral therapy (ART) if positive and Pre-Exposure Prophylaxis (PrEP) for those eligible (based on national guidelines) and negative.

SoC at Primary Health care clinics includes, contraception, HIV testing and ART if positive and PrEP for those eligible and negative.

Population: The eligible population are \~26,000 15-30-year-old residing in 40 administrative areas (clusters) of the uMkhanyakude district in rural KwaZulu Natal. The 40 clusters will undergo a stratified randomisation to early versus delayed intervention roll out.

Data collection: Research data will be collected from four sources: i) three random representative surveys of n= 2000, 15-30-year-olds; ii) programme, process, and clinical data; iii) qualitative data collected during the process evaluation iv) cost data using bottom-up ingredient-based costing and top-down costing using the budgets and expenditure reports.

Study Duration: 36 months.

Read the detailed description

This implementation trial aims to measure the effect, of 'social mobilisation into decentralised SRH services that provide tailored HIV prevention' on the prevalence of transmissible HIV amongst young people aged 15-30, as well as cost-effectiveness, practicability and reach.

Trial design: investigators will use a cRCT and realist process evaluation with costings. The stepped wedge design consists of 40 clusters (administrative areas) randomised to two intervention steps (early and delayed), 15 months apart. The investigators compare prevalence of transmissible HIV and uptake of risk-informed HIV prevention in intervention areas with contemporaneous controls. The investigators will conduct a cost effectiveness analysis and use a realist process evaluation to interrogate the extent to which the intervention components deliver according to the theory of change and support demand, uptake and retention in risk-differentiated biomedical HIV prevention amongst young people. Investigators will use the process evaluation data to inform any modifications within the intervention arm and to inform stop/go decisions at the end of step1.

Study setting: The study is taking place in the uMkhanyakude district in rural KZN, which is mostly rural with over 85% youth unemployment and a high burden of HIV.

Study population and eligibility criteria: About 26,000 young people aged 15-30 residing in 40 administrative areas (clusters) of the uMkhanyakude district in rural KwaZulu Natal are eligible to receive the intervention and control services. Investigators use the AHRI health and demographic surveillance as a sampling frame to randomly select three separate cross-sectional samples of n=3600 (90 per cluster) 15-30-year-olds stratified by gender at baseline, midpoint (before the second step of scale up) and end-line to measure trial outcome. Based on previous studies in this setting, investigators anticipate that \~2800 will be contactable and eligible and that n=2000 (\~50 per cluster) men and women aged 15-30, will be willing and able to provide consent to be included in the study.

Study interventions, eligibility criteria and outcomes are described below

Sample size calculations: Based on current data 8% of the 15-30-year old's have a transmissible HIV viral load and \~35% are aware of their HIV status and either on PrEP or on ART and undetectable. With 50 per cluster (n=2000 15-30-year-olds total) in each of the three survey waves, assuming an ICC within waves of 0.1 for transmissible HIV and 0.4 for intervention uptake and a decay (autocorrelation) for both outcomes between waves of 0.9, our two-step stepped wedge trial design provides 90% power to detect an increase from 35% to 47% in uptake of intervention and 80% power to show a reduction of proportion with transmissible HIV from 8% to 4% between the intervention and standard of care. The estimates of ICC are based on the coefficient of variation (k) between clusters estimated in the range 0.7-1.0 for intervention uptake seen in a trial of peer navigators in the same area. In these calculations investigators assume that the intervention effect is fully realised within 12 months (gap from baseline to midline survey) and does not decline. Investigators will also report the intervention effect after 27 months (gap from baseline to end line).

Data collection:

(i) Following informed consent, the participants will complete a 20-30-minute interviewer administered RedCap survey in IsiZulu. Sensitive questions in this survey are self-filled. Questions will include awareness of HIV status, awareness and uptake of PrEP/VMMC, ART, exposure to youth groups, peer navigators, and mobile clinics, sociodemographic, sexual risk (e.g., number of partners, condom use, and transactional sex), reproductive health (e.g., contraception, pregnancy, fatherhood and VMMC); and mental health (PHQ9, alcohol and drug use). Interviewers will offer point of care HIV testing and collect Dry Blood Spots (DBS) or pediatric blood collection tubes (\<2ml) for HIV ELISA and viral load testing on those that test positive.

(ii) Investigators will measure linkage to ART/PrEP through identifying eligible young people who link for PrEP/ prevention counselling or ART initiation within mobile services. Investigators will use the bar-coded vouchers and other identification within RedCap to confirm linkage. Within the 11 PHC investigators will use the ClinLink software which is effective in identifying individuals in the surveillance area and collecting reasons for attending when they attend PHC. Investigators will look at reasons for attending the 11 PHC in all 15-30-year-olds through CliniLink as well as ART and PrEP data in tiernet linked to the HDSS. Investigators will use an algorithm to identify which cluster the individual came from, including the bar code on the coupon they bring, their name, age, phone number, their HDSS number, and area of residence.

(iii) Investigators will collect data on uptake and retention in all components of the intervention in all 26,000 15-30-year-olds in the study area. a) Investigators will collect the programme data records from the peer navigator tools. This is a RedCap participant support management tool on the peer navigator tablets. They record the unique ID of the young people they meet and the GPS co-ordinates, demographic, and contact details of those who accept health promotion. They then complete a psychosocial and health needs assessment and record the health promotion, service and/or referral provided. All referrals are made using barcoded referral slips that are scanned into the tablet. They will finally generate an action plan including follow-up plans for those who need ongoing support e.g., on PrEP or ART. b) Youth groups attendance will be recorded (by scanning in barcodes). c) Investigators will collect clinical data from the RedCap clinical management tool. Investigators will use the clinical data to record HIV testing, ART uptake if positive, PrEP eligibility screening and PrEP uptake if negative, and other services received. Investigators will also measure retention, adherence, and reasons for stopping and/or restarting PrEP. By using this programme data that links the community outreach with the clinical services investigators will understand the reach and coverage of the programme. This includes coverage of treatment and reductions in HIV acquisition as a proportion of all young people in the area and as a proportion of the young people reached by the programme. Investigators will interrogate any systematic differences in uptake by gender, age and socio-economic characteristics and explore what works for whom and how through the process evaluation.

(iv) Qualitative data will include IDIs will be conducted peer navigators (n=10), nurses/clinical research assistants (n=6) stationed in clinics in the participating communities, and a purposive sample of young people aged 15-30 years (n=50). The interviews will be conducted by ARHI trained fieldworkers including a senior social scientist in English and isiZulu. This will enable the researchers to understand, contextualise and explore some of the issues around the intervention. To limit disturbances and ensure privacy, the IDI will be conducted in a private space suitable for the participant, and audio recorded with interviewees' consents. Researchers will conduct natural group discussions with community group and intervention delivery staff (n=7; 1 with clinic staff, 2 peer navigators' groups and 4 community groups (older men, older women and younger men and younger women). The group discussion will contain 6-8 people and will last approximately 120 minutes.

(v) The study team will work closely with HE2RO to establish costs. Investigators will adapt the data collection tools that were used in the STAR trial to measure the costs of the peer navigator intervention to collect bottom-up ingredient-based costs. This will be complemented with a top-down costing approach using the AHRI study budgets and expenditure reports.

Analysis: An intention-to-treat analysis will be conducted for each primary outcome. A significance level of 0.05 will be used unless otherwise stated. A detailed statistical analysis plan will be completed prior to the end of data collection.

To quantify the effect of the intervention on sexually transmissible HIV, the trial statistician will fit a logistic regression model to estimate the odds ratio (OR) and 95% confidence interval (CI), adjusting for design factors and survey wave, acknowledging the clustering of the data through generalized estimating equations. Since randomisation may result in an imbalance in the distribution of HIV risk factors across the intervention steps, they will also adjust for pre-specified predictors known to be associated with HIV transmission risk in this population at cluster and individual level.

To measure the uptake of universal risk informed HIV prevention intervention, the study statistician will calculate the proportion and 95% CI of participants who consent to participate in the intervention and are aware of HIV status; on treatment if positive; and have undergone risk assessment by peer navigators or SRH clinic if HIV negative (and taken up PrEP if HIV negative and eligible).

To examine the cost of transmissible HIV averted, investigators will measure the costs in intervention and control arms and compare the two arms in their cost-effectiveness in achieving endpoints, i.e., the cost per transmissible HIV case averted and the cost per case linked to risk differentiated biosocial HIV prevention. To establish costs, the investigators will use both a bottom-up ingredient-based costing approach and a top-down costing approach using the study budgets and expenditure reports.

Interim analyses: To inform modifications (6months): In the first quarter of the intervention arm, investigators will look at the uptake of the three different components of the intervention. Based on the pilot data investigators expect n=13,000 (50%) of all 15-30-year-olds receive at least one structured assessment from peer navigators; 8,000 (30%) of all 15-30-year-olds are seen in sexual health services; and 1000 (7%) will have engaged with effective use of PrEP. To be on track to reach these targets, by the first quarter of intervention role out in all 20 early clusters investigators would expect peers to have conducted needs assessment on n>=2000; n>=1000 would have been seen in the mobile clinic and n>= 75 would have started PrEP/ART. If these parameters aren't met in the first quarter the process data will be used to enhance the intervention. To inform a stop/continue decision: By the end of step 1 if less 40% (n\<5000) of 15-30-year-olds undergo a peer-led needs assessment and/or less than n\< 300 - i.e., less than one third of the 900 we expect to be eligible for risk informed PrEP - attend the SRH clinic investigators would consider stopping the intervention.

In-depth Interview Interviews will be based on a topic guide, and it is estimated that they will take up to an hour. They will be recorded and transcribed verbatim, with the permission of participants. Data from the IDIs will be analysed using NVIVO software. The software will be used for categorisation and coding of identified themes from the interview transcripts. Identified themes (including participants' quotes) and interview transcripts will be reviewed and compared by the research team for inconsistencies and adequate representation of participants' comments. A thematic analysis of all interview data will be conducted using framework approach.

03

Conditions studied

  • HIV-1-infection
  • Sexually Transmitted Diseases
04

Who can participate

Ages eligible
15 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Resident in the cluster
  • Any gender
  • Aged 15-30
  • If aged 18-30 and able and willing to consent to participate
  • If aged 15-17, able and willing to assent and whose guardian or parent are able and willing to consent to their participation.

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to provide consent
  • Aged 14 or less
  • aged 31 or more
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
8,716 participants (actual)

Study arms

  • Experimental
    community-based differentiated biosocial HIV prevention (incl. PrEP) with SRH

    The intervention is available to all 15-30 year olds residing in the intervention cluster. Area based peer navigators mobilise all young people living in their cluster. They provide sexual health promotion, condoms, HIV self-tests, pregnancy test, and conduct structured psychosocial and health needs assessment with the young people they support. Based on the needs assessment they develop a tailored plan which includes, varying degrees of peer-mentorship and psychosocial support, lay-counselling and ART/PrEP adherence support. The peer navigators refer young people to mobile SRH services. The mobile SRH services provide gender and HIV status neutral nurse-led HIV testing, Individualised risk assessments for HIV care and PrEP, contraception and wider SRH services. The nurses liaise with the peer navigators to provide ongoing support for 3-monthly follow-ups with repeat HIV testing, adherence support and PrEP/ART/contraception refills.

    Combination Product: Community-based differentiated HIV prevention incl.PrEP with SRH

  • Active comparator
    Standard of Care

    SOC is available to all young people in the delayed clusters. Care is provided in a nurse led Primary Health Clinics (PHC) to young people who attend the clinic. This includes HIV counselling and point of care testing, immediate initiation of ART if positive and PrEP if negative and eligible according to South African National PrEP guidelines. This is followed by a 3-monthly follow-up with repeat HIV testing, safety bloods, clinic-based counselling and adherence support and PrEP/ART refills. Clinic attendees are offered family planning support and syndromic management for STIs (as per South African National Department of Health Guideline).

    Other: Primary Health Clinic based HIV prevention and care

Interventions

  • Combination productCommunity-based differentiated HIV prevention incl.PrEP with SRH

    Community-based model of care, that consists of social mobilisation by area-based peer-navigator into decentralised sexual reproductive health (SRH) and HIV care (incl. PrEP).

  • OtherPrimary Health Clinic based HIV prevention and care

    Primary Health Clinic (PHC) based initiation and follow-up with HIV testing and standard HIV prevention and treatment package. Family planning support and syndromic management for STIs as per South African National Department of Health Guideline.

06

What researchers measure

Primary outcomes

  1. Prevalence of sexually transmitted HIV

    The proportion of those aged 15-30 who are HIV positive and have a detectable HIV viral load defined as having an HIV viral load of \>= 400 copies per ml, in the intervention arm compared to control

    Time frame: 36 months

  2. The uptake of risk informed biomedical HIV prevention

    The proportion of participants who are aware of HIV status; on treatment if positive; and have undergone risk assessment by peer navigators or SRH clinic if HIV negative (and taken up PrEP if HIV negative and eligible) in the intervention arm compared to control.

    Time frame: 36 months

  3. The cost of transmissible HIV averted.

    The cost per transmissible HIV case averted and the cost per case linked to risk differentiated biosocial HIV prevention.

    Time frame: 36 months

Secondary outcomes

  1. Uptake of contraception

    The proportion of females aged 15-30 who are on effective contraception in the intervention compared to control arm.

    Time frame: 36 months

  2. Uptake of voluntary male medical circumcision

    Proportion of men aged 15-30 who have undergone voluntary male medical circumcision in the intervention compared to control arm.

    Time frame: 36 months

  3. Prevalence of Sexually Transmitted Infections

    Proportion of 15-30 year olds who test positive for gonorrhoea, chlamydia or trichomonas in the intervention compared to control arm.

    Time frame: 36 months

  4. Teenage pregnancy and fatherhood

    Proportion of those aged 15-19 who have become pregnant or fathered a child in the intervention compared to control arm.

    Time frame: 36 months

  5. Proportion of men and women aged 15-30 at risk of acquiring HIV or transmitting HIV

    Among those who are HIV negative or unknown, sexually active, \>1 lifetime partner + condom-less sex + no PrEP; and among those who are HIV positive + sexually active + condom-less sex + not on ART and/or VL \>400 copies per ml - comparing the intervention and control arm

    Time frame: 36 months

  6. Uptake of PrEP

    Comparison of the proportion of all eligible HIV negative participants who are initiated on PrEP in the intervention compared to the control arm

    Time frame: 36 months

  7. Cost per case linked to HIV care and Prevention

    comparison of costs in intervention and control arms of the cost per case linked to universal risk informed HIV prevention intervention (PrEP eligibility assessment (HIV-) and cost per case started on ART (HIV+)

    Time frame: 36 months

  8. Acceptability and reach of peer support

    Proportion of all 15-30 year olds residing in the HDSS who have at least one peer navigator needs assessment per year, disaggregated by gender, age and sociodemographics

    Time frame: 36 months

  9. Acceptability and reach of mobile SRH clinics

    Proportion of all 15-30 year olds residing in the HDSS who have at least one mobile clinic attendance per year, disaggregated by gender, age and sociodemographics

    Time frame: 36 months

  10. Fidelity

    Proportion of all participants who engaged with or participated in 60% of the intervention components offered to them

    Time frame: 36 months

Other outcomes

  1. Common mental disorder

    The proportion of 15-30 year olds that screen positive for CMD in the intervention arm compared to the control arm

    Time frame: 36 months

  2. Retention in PrEP

    The proportion of 15-30 year olds that start ART/PrEP and attend at least one follow-up visit

    Time frame: 36 months

07

Study locations

1 site
  • Africa Health Research Institute
    Somkele, KwaZulu-Natal, South Africa
08

References and documents

Publications

  • Busang J, Ngoma N, Zuma T, Herbst C, Okesola N, Chimbindi N, Dreyer J, Smit T, Bird K, Mtolo L, Behuhuma O, Hanekom W, Herbst K, Lebina L, Seeley J, Copas A, Baisley K, Shahmanesh M. Person-centred HIV care and prevention for youth in rural South Africa: preliminary implementation findings from Thetha Nami ngithethe nawe stepped-wedge trial of peer-navigator mobilization into mobile sexual health services. J Int AIDS Soc. 2025 Sep;28 Suppl 5(Suppl 5):e70032. doi: 10.1002/jia2.70032. PubMed 41059644 ↗
  • Busang J, Zuma T, Herbst C, Okesola N, Chimbindi N, Dreyer J, Mtshali N, Smit T, Ngubane S, Hlongwane S, Gumede D, Jalazi A, Mdluli S, Bird K, Msane S, Danisa P, Hanekom W, Lebina L, Behuhuma N, Hendrickson C, Miot J, Seeley J, Harling G, Jarolimova J, Sherr L, Copas A, Baisley K, Shahmanesh M. Thetha Nami ngithethe nawe (Let's Talk): a stepped-wedge cluster randomised trial of social mobilisation by peer navigators into community-based sexual health and HIV care, including pre-exposure prophylaxis (PrEP), to reduce sexually transmissible HIV amongst young people in rural KwaZulu-Natal, South Africa. BMC Public Health. 2023 Aug 15;23(1):1553. doi: 10.1186/s12889-023-16262-x. PubMed 37582746 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Study Protocol, SAP and ICF's are available now and Analytic code as soon as it is finalised for the primary analysis.

Access criteria: Everyone. It will be available at time of analysis of primary outcome through AHRI data repository.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Feb 2026, 45 months.

Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's 45 months is above that.

Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2022
First posted
Jun 6, 2022
StartActual
May 26, 2022
Primary completionActual
Feb 28, 2026
CompletionActual
Mar 1, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05405582
Lead sponsor
Africa Health Research Institute
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
May 26, 2022
Primary completion
Feb 28, 2026
Completion
Mar 1, 2026
Last update
Jul 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion